Search

Your search keyword '"Slosky, David"' showing total 49 results
Start Over Author "Slosky, David"
49 results on '"Slosky, David"'

1. Clonal hematopoiesis and inflammation in the vasculature: CHIVE, a prospective, longitudinal clonal hematopoiesis cohort and biorepository.

Author

Shannon, Morgan, Heimlich, J, Olson, Sydney, Debevec, Ariana, Copeland, Zachary, Kishtagari, Ashwin, Vlasschaert, Caitlyn, Snider, Christina, Silver, Alexander, Brown, Donovan, Spaulding, Travis, Bhatta, Manasa, Pugh, Kelly, Stockton, Shannon, Ulloa, Jessica, Xu, Yaomin, Baljevic, Muhamed, Moslehi, Javid, Jahangir, Eiman, Ferrell, P, Slosky, David, Bick, Alexander, and Savona, Michael

Subjects
Humans, Clonal Hematopoiesis, Inflammation, Prospective Studies, Female, Male, Middle Aged, Aged, Registries, Hematologic Neoplasms, Mutation, Adult
Abstract

Clonal hematopoiesis (CH) is an age-associated phenomenon leading to an increased risk of both hematologic malignancy and nonmalignant organ dysfunction. Increasingly available genetic testing has made the incidental discovery of CH clinically common yet evidence-based guidelines and effective management strategies to prevent adverse CH health outcomes are lacking. To address this gap, the prospective CHIVE (clonal hematopoiesis and inflammation in the vasculature) registry and biorepository was created to identify and monitor individuals at risk, support multidisciplinary CH clinics, and refine taxonomy and standards of practice for CH risk mitigation. Data from the first 181 patients enrolled in this prospective registry recapitulate the molecular epidemiology of CH from biobank-scale retrospective studies, with DNMT3A, TET2, ASXL1, and TP53 as the most commonly mutated genes. Blood counts across all hematopoietic lineages trended lower in patients with CH. In addition, patients with CH had higher rates of end organ dysfunction, in particular chronic kidney disease. Among patients with CH, variant allele frequency was independently associated with the presence of cytopenias and progression to hematologic malignancy, whereas other common high-risk CH clone features were not clear. Notably, accumulation of multiple distinct high-risk clone features was also associated with cytopenias and hematologic malignancy progression, supporting a recently published CH risk score. Surprisingly, ∼30% of patients enrolled in CHIVE from CH clinics were adjudicated as not having clonal hematopoiesis of indeterminate potential, highlighting the need for molecular standards and purpose-built assays in this field. Maintenance of this well-annotated cohort and continued expansion of CHIVE to multiple institutions are underway and will be critical to understanding how to thoughtfully care for this patient population.

Published
2024

2. COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease.

Author

Moey, Melissa, Hennessy, Cassandra, French, Benjamin, Warner, Jeremy, Tucker, Matthew, Hausrath, Daniel, Shah, Dimpy, DeCara, Jeanne, Bakouny, Ziad, Labaki, Chris, Choueiri, Toni, Dent, Susan, Akhter, Nausheen, Ismail-Khan, Roohi, Tachiki, Lisa, Slosky, David, Polonsky, Tamar, Awosika, Joy, Crago, Audrey, Wise-Draper, Trisha, Balanchivadze, Nino, Hwang, Clara, Fecher, Leslie, Gomez, Cyndi, Hayes-Lattin, Brandon, Glover, Michael, Shah, Sumit, Gopalakrishnan, Dharmesh, Griffiths, Elizabeth, Kwon, Daniel, Koshkin, Vadim, Mahmood, Sana, Bashir, Babar, Nonato, Taylor, Razavi, Pedram, McKay, Rana, Nagaraj, Gayathri, Oligino, Eric, Puc, Matthew, Tregubenko, Polina, Wulff-Burchfield, Elizabeth, Xie, Zhuoer, Halfdanarson, Thorvardur, Farmakiotis, Dimitrios, Klein, Elizabeth, Robilotti, Elizabeth, Riely, Gregory, Durand, Jean-Bernard, Hayek, Salim, Kondapalli, Lavanya, Berg, Stephanie, OConnor, Timothy, Bilen, Mehmet, Castellano, Cecilia, Accordino, Melissa, Sibel, Blau, Weissmann, Lisa, Jani, Chinmay, Flora, Daniel, Rudski, Lawrence, Dutra, Miriam, Nathaniel, Bouganim, Ruíz-García, Erika, Vilar-Compte, Diana, Gupta, Shilpa, Morgans, Alicia, and Nohria, Anju

Subjects
COVID-19 outcomes, Cancer, Cardio-oncology, Cardiovascular disease
Abstract

BACKGROUND: Data regarding outcomes among patients with cancer and co-morbid cardiovascular disease (CVD)/cardiovascular risk factors (CVRF) after SARS-CoV-2 infection are limited. OBJECTIVES: To compare Coronavirus disease 2019 (COVID-19) related complications among cancer patients with and without co-morbid CVD/CVRF. METHODS: Retrospective cohort study of patients with cancer and laboratory-confirmed SARS-CoV-2, reported to the COVID-19 and Cancer Consortium (CCC19) registry from 03/17/2020 to 12/31/2021. CVD/CVRF was defined as established CVD or no established CVD, male ≥ 55 or female ≥ 60 years, and one additional CVRF. The primary endpoint was an ordinal COVID-19 severity outcome including need for hospitalization, supplemental oxygen, intensive care unit (ICU), mechanical ventilation, ICU or mechanical ventilation plus vasopressors, and death. Secondary endpoints included incident adverse CV events. Ordinal logistic regression models estimated associations of CVD/CVRF with COVID-19 severity. Effect modification by recent cancer therapy was evaluated. RESULTS: Among 10,876 SARS-CoV-2 infected patients with cancer (median age 65 [IQR 54-74] years, 53% female, 52% White), 6253 patients (57%) had co-morbid CVD/CVRF. Co-morbid CVD/CVRF was associated with higher COVID-19 severity (adjusted OR: 1.25 [95% CI 1.11-1.40]). Adverse CV events were significantly higher in patients with CVD/CVRF (all p

Published
2023

3. Age- and Sex-Related Differences in Patients With Wild-Type Transthyretin Amyloidosis: Insights From THAOS

Author

Emdin, Michele, Hanna, Mazen, Azevedo, Olga, Lino Cirami, Calogero, Gonzalez Costello, Jose, Slosky, David, Moelgaard, Henning, Nativi Nicolau, Jose, Hummel, Scott, Jeon, Eun-Seok, Fine, Nowell, Murali, Srinivas, Miller, Edward, Shah, Sanjiv, Witteles, Ronald, Waddington-Cruz, Marcia, Lenihan, Daniel, Sekijima, Yoshiki, Van Cleemput, Johan, Correia, Edileide de Barros, Cariou, Eve, Quan, Dianna, Freimer, Miriam, Steidley, David, Hüsing-Kabar, Anna, Plante-Bordeneuve, Violaine, Nienhuis, Hans, Wixner, Jonas, Ralph, Jeffrey, Ventura, Hector, Zivkovic, Sasa, Delgado, Diego, Fernandéz Torrón, Roberto, Gottlieb, Stephen, Cotts, William, Tallaj, Jose, Brunkhorst, Robert, Polydefkis, Michael, Mueller, Christopher, Tschoepe, Carsten, Gonzalez Moreno, Juan, Sarswat, Nitasha, Luo, Jin, Tauras, James, Warner, Alberta, Mora-Ayestaran, Nerea, Dispenzieri, Angela, Kristen, Arnt V., Maurer, Mathew S., Diemberger, Igor, Drachman, Brian M., Grogan, Martha, Gupta, Pritam, Glass, Oliver, Amass, Leslie, and Garcia-Pavia, Pablo

Published
2024
Full Text
View/download PDF

4. Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.

Author

Cornell, Robert, Ky, Bonnie, Weiss, Brendan, Dahm, Cherie, Gupta, Deepak, Du, Liping, Carver, Joseph, Cohen, Adam, Engelhardt, Brian, Garfall, Alfred, Goodman, Stacey, Harrell, Shelton, Kassim, Adetola, Jadhav, Trafina, Jagasia, Madan, Moslehi, Javid, OQuinn, Rupal, Savona, Michael, Slosky, David, Smith, Amanda, Stadtmauer, Edward, Vogl, Dan, Waxman, Adam, and Lenihan, Daniel

Subjects
Adult, Aged, Aged, 80 and over, Bortezomib, Cardiovascular Diseases, Disease-Free Survival, Electrocardiography, Female, Heart Diseases, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Molecular Targeted Therapy, Multiple Myeloma, Natriuretic Peptide, Brain, Neoplasm Recurrence, Local, Oligopeptides, Prospective Studies, Proteasome Inhibitors, Risk Factors, Time-to-Treatment, Treatment Outcome, Troponin I, Troponin T
Abstract

PURPOSE: Cardiovascular adverse events (CVAEs) can occur during proteasome inhibitor (PI) therapy. We conducted a prospective, observational, multi-institutional study to define risk factors and outcomes in patients with multiple myeloma (MM) receiving PIs. PATIENTS AND METHODS: Patients with relapsed MM initiating carfilzomib- or bortezomib-based therapy underwent baseline assessments and repeated assessments at regular intervals over 6 months, including cardiac biomarkers (troponin I or T, brain natriuretic peptide [BNP], and N-terminal proBNP), ECG, and echocardiography. Monitoring occurred over 18 months for development of CVAEs. RESULTS: Of 95 patients enrolled, 65 received carfilzomib and 30 received bortezomib, with median 25 months of follow-up. Sixty-four CVAEs occurred, with 55% grade 3 or greater in severity. CVAEs occurred in 51% of patients treated with carfilzomib and 17% of those treated with bortezomib (P = .002). Median time to first CVAE from treatment start was 31 days, and 86% occurred within the first 3 months. Patients receiving carfilzomib-based therapy with a baseline elevated BNP level higher than 100 pg/mL or N-terminal proBNP level higher than 125 pg/mL had increased risk for CVAE (odds ratio, 10.8; P < .001). Elevated natriuretic peptides occurring mid-first cycle of treatment with carfilzomib were associated with a substantially higher risk of CVAEs (odds ratio, 36.0; P < .001). Patients who experienced a CVAE had inferior progression-free survival (log-rank P = .01) and overall survival (log-rank P < .001). PI therapy was safely resumed in 89% of patients, although 41% required chemotherapy modifications. CONCLUSION: CVAEs are common during PI therapy for relapsed MM, especially with carfilzomib, particularly within the first 3 months of therapy. CVAEs were associated with worse overall outcomes, but usually, discontinuation of therapy was not required. Natriuretic peptides were highly predictive of CVAEs; however, validation of this finding is necessary before uniform incorporation into the routine management of patients receiving carfilzomib.

Published
2019

5. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey

Author

Barroso, Fabio Adrian, Van Cleemput, Johan, Fine, Nowell, Schmidt, Hartmut, Gess, Burkhard, Moelgaard, Henning, Planté-Bordeneuve, Violaine, Adams, David, Inamo, Jocelyn, Vita, Giuseppe, Cirami, Calogero Lino, Luigetti, Marco, Emdin, Michele, Sekijima, Yoshiki, Yamashita, Taro, Jeon, Eun-Seok, Gonzalez Duarte Briseno, Maria Alejandra, Nienhuis, Hans, Azevedo, Olga, Campistol Plana, Josep Maria, Moreno, Juan Gonzalez, Costello, Jose Gonzalez, Wixner, Jonas, Parman, Yesim, Shah, Sanjiv, Quan, Dianna, Marburger, Tessa, Polydefkis, Michael, Gottlieb, Stephen, Ralph, Jeffrey, Sarswat, Nitasha, Luo, Jin, Murali, Srinivas, Cotts, William, Drachman, Brian, Steidley, David, Hummel, Scott, Slosky, David, Ventura, Hector, Jacoby, Daniel, Hoffman, James, Tauras, James, Zivkovic, Sasa, Tallaj, Jose, Lenihan, Daniel, Mueller, Christopher, Nativi-Nicolau, Jose, Siu, Alfonso, Dispenzieri, Angela, Maurer, Mathew S., Rapezzi, Claudio, Kristen, Arnt V., Garcia-Pavia, Pablo, LoRusso, Samantha, Waddington-Cruz, Márcia, Lairez, Olivier, Witteles, Ronald, Chapman, Doug, Amass, Leslie, and Grogan, Martha

Published
2021
Full Text
View/download PDF

6. Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS

Author

van Cleemput, Johan, Waddington-Cruz, Marcia, Schmidt, Hartmut, Dillmann, Klaus-Ulrich, Mølgaard, Henning, Moreno, Juan Gonzalez, Costello, Jose Gonzalez, Beamud, Francisco Munoz, Davila, Lucia Galan, Adams, David, Inamo, Jocelyn, Lairez, Olivier, Vita, Giuseppe, Merlini, Giampaolo, Cirami, Calogero Lino, Luigetti, Marco, Emdin, Michele, Sekijima, Yoshiki, Jeon, Eun-Seok, Oh, Jeeyoung, Gonzalez Duarte Briseno, Maria Alejandra, Nienhuis, Hans, Coelho, Teresa, Conceicao, Isabel, Azevedo, Olga, Badelita, Sorina, Press, Rayomand, Parman, Yesim, Shah, Sanjiv, Quan, Dianna, Marburger, Tessa, Polydefkis, Michael, Witteles, Ronald, Gottlieb, Stephen, Sarswat, Nitasha, Drachman, Brian, Steidley, David, Hummel, Scott, Slosky, David, Jacoby, Daniel, Nativi-Nicolau, Jose, Tauras, James, Zivkovic, Sasa, Tallaj, Jose, Lenihan, Daniel, Caponetti, Angelo Giuseppe, Rapezzi, Claudio, Gagliardi, Christian, Milandri, Agnese, Dispenzieri, Angela, Kristen, Arnt V., Wixner, Jonas, Maurer, Mathew S., Garcia-Pavia, Pablo, Tournev, Ivailo, Planté-Bordeneuve, Violaine, Chapman, Douglass, and Amass, Leslie

Published
2021
Full Text
View/download PDF

7. Clonal Hematopoiesis and Inflammation in the VasculaturE (CHIVE): a prospective, longitudinal cohort and biorepository

Author

Shannon, Morgan L., primary, Heimlich, Jonathan Brett, additional, Olson, Sydney, additional, Debevec, Ariana, additional, Copeland, Zachary, additional, Kishtagari, Ashwin, additional, Vlasschaert, Caitlyn, additional, Snider, Christina A., additional, Silver, Alexander J, additional, Brown, Donovan, additional, Spaulding, Travis P., additional, Bhatta, Manasa Ram, additional, Pugh, Kelly, additional, Stockton, Shannon S., additional, Ulloa, Jessica, additional, Xu, Yaomin, additional, Baljevic, Muhamed, additional, Moslehi, Javid, additional, Jahangir, Eiman, additional, Ferrell, Paul Brent, additional, Slosky, David Alan, additional, Bick, Alexander G., additional, and Savona, Michael R., additional

Published
2024
Full Text
View/download PDF

9. COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease

Author

Moey, Melissa Y.Y., primary, Hennessy, Cassandra, additional, French, Benjamin, additional, Warner, Jeremy L., additional, Tucker, Matthew D., additional, Hausrath, Daniel J., additional, Shah, Dimpy P., additional, DeCara, Jeanne M., additional, Bakouny, Ziad, additional, Labaki, Chris, additional, Choueiri, Toni K., additional, Dent, Susan, additional, Akhter, Nausheen, additional, Ismail-Khan, Roohi, additional, Tachiki, Lisa, additional, Slosky, David, additional, Polonsky, Tamar S., additional, Awosika, Joy A., additional, Crago, Audrey, additional, Wise-Draper, Trisha, additional, Balanchivadze, Nino, additional, Hwang, Clara, additional, Fecher, Leslie A., additional, Gomez, Cyndi Gonzalez, additional, Hayes-Lattin, Brandon, additional, Glover, Michael J., additional, Shah, Sumit A., additional, Gopalakrishnan, Dharmesh, additional, Griffiths, Elizabeth A., additional, Kwon, Daniel H., additional, Koshkin, Vadim S., additional, Mahmood, Sana, additional, Bashir, Babar, additional, Nonato, Taylor, additional, Razavi, Pedram, additional, McKay, Rana R., additional, Nagaraj, Gayathri, additional, Oligino, Eric, additional, Puc, Matthew, additional, Tregubenko, Polina, additional, Wulff-Burchfield, Elizabeth M., additional, Xie, Zhuoer, additional, Halfdanarson, Thorvardur R., additional, Farmakiotis, Dimitrios, additional, Klein, Elizabeth J., additional, Robilotti, Elizabeth V., additional, Riely, Gregory J., additional, Durand, Jean-Bernard, additional, Hayek, Salim S., additional, Kondapalli, Lavanya, additional, Berg, Stephanie, additional, O'Connor, Timothy E., additional, Bilen, Mehmet A., additional, Castellano, Cecilia, additional, Accordino, Melissa K., additional, Sibel, Blau, additional, Weissmann, Lisa B., additional, Jani, Chinmay, additional, Flora, Daniel B., additional, Rudski, Lawrence, additional, Dutra, Miriam Santos, additional, Nathaniel, Bouganim, additional, Ruíz-García, Erika, additional, Vilar-Compte, Diana, additional, Gupta, Shilpa, additional, Morgans, Alicia, additional, and Nohria, Anju, additional

Published
2023
Full Text
View/download PDF

10. COVID-19 Severity and Cardiovascular Outcomes in SARS-CoV-2-Infected Patients With Cancer and Cardiovascular Disease

Author

Moey, Melissa Y.Y., Hennessy, Cassandra, French, Benjamin, Warner, Jeremy L., Tucker, Matthew D., Hausrath, Daniel J., Shah, Dimpy P., DeCara, Jeanne M., Bakouny, Ziad, Labaki, Chris, Choueiri, Toni K., Dent, Susan, Akhter, Nausheen, Ismail-Khan, Roohi, Tachiki, Lisa, Slosky, David, Polonsky, Tamar S., Awosika, Joy A., Crago, Audrey, Wise-Draper, Trisha, Balanchivadze, Nino, Hwang, Clara, Fecher, Leslie A., Gomez, Cyndi Gonzalez, Hayes-Lattin, Brandon, Glover, Michael J., Shah, Sumit A., Gopalakrishnan, Dharmesh, Griffiths, Elizabeth A., Kwon, Daniel H., Koshkin, Vadim S., Mahmood, Sana, Bashir, Babar, Nonato, Taylor, Razavi, Pedram, McKay, Rana R., Nagaraj, Gayathri, Oligino, Eric, Puc, Matthew, Tregubenko, Polina, Wulff-Burchfield, Elizabeth M., Xie, Zhuoer, Halfdanarson, Thorvardur R., Farmakiotis, Dimitrios, Klein, Elizabeth J., Robilotti, Elizabeth V., Riely, Gregory J., Durand, Jean-Bernard, Hayek, Salim S., Kondapalli, Lavanya, Berg, Stephanie, O'Connor, Timothy E., Bilen, Mehmet A., Castellano, Cecilia, Accordino, Melissa K., Sibel, Blau, Weissmann, Lisa B., Jani, Chinmay, Flora, Daniel B., Rudski, Lawrence, Dutra, Miriam Santos, Nathaniel, Bouganim, Ruíz-García, Erika, Vilar-Compte, Diana, Gupta, Shilpa, Morgans, Alicia, Nohria, Anju, Moey, Melissa Y.Y., Hennessy, Cassandra, French, Benjamin, Warner, Jeremy L., Tucker, Matthew D., Hausrath, Daniel J., Shah, Dimpy P., DeCara, Jeanne M., Bakouny, Ziad, Labaki, Chris, Choueiri, Toni K., Dent, Susan, Akhter, Nausheen, Ismail-Khan, Roohi, Tachiki, Lisa, Slosky, David, Polonsky, Tamar S., Awosika, Joy A., Crago, Audrey, Wise-Draper, Trisha, Balanchivadze, Nino, Hwang, Clara, Fecher, Leslie A., Gomez, Cyndi Gonzalez, Hayes-Lattin, Brandon, Glover, Michael J., Shah, Sumit A., Gopalakrishnan, Dharmesh, Griffiths, Elizabeth A., Kwon, Daniel H., Koshkin, Vadim S., Mahmood, Sana, Bashir, Babar, Nonato, Taylor, Razavi, Pedram, McKay, Rana R., Nagaraj, Gayathri, Oligino, Eric, Puc, Matthew, Tregubenko, Polina, Wulff-Burchfield, Elizabeth M., Xie, Zhuoer, Halfdanarson, Thorvardur R., Farmakiotis, Dimitrios, Klein, Elizabeth J., Robilotti, Elizabeth V., Riely, Gregory J., Durand, Jean-Bernard, Hayek, Salim S., Kondapalli, Lavanya, Berg, Stephanie, O'Connor, Timothy E., Bilen, Mehmet A., Castellano, Cecilia, Accordino, Melissa K., Sibel, Blau, Weissmann, Lisa B., Jani, Chinmay, Flora, Daniel B., Rudski, Lawrence, Dutra, Miriam Santos, Nathaniel, Bouganim, Ruíz-García, Erika, Vilar-Compte, Diana, Gupta, Shilpa, Morgans, Alicia, and Nohria, Anju

Abstract

BACKGROUND: Data regarding outcomes among patients with cancer and co-morbid cardiovascular disease (CVD)/cardiovascular risk factors (CVRF) after SARS-CoV-2 infection are limited. OBJECTIVES: To compare Coronavirus disease 2019 (COVID-19) related complications among cancer patients with and without co-morbid CVD/CVRF. METHODS: Retrospective cohort study of patients with cancer and laboratory-confirmed SARS-CoV-2, reported to the COVID-19 and Cancer Consortium (CCC19) registry from 03/17/2020 to 12/31/2021. CVD/CVRF was defined as established CVD RESULTS: Among 10,876 SARS-CoV-2 infected patients with cancer (median age 65 [IQR 54-74] years, 53% female, 52% White), 6253 patients (57%) had co-morbid CVD/CVRF. Co-morbid CVD/CVRF was associated with higher COVID-19 severity (adjusted OR: 1.25 [95% CI 1.11-1.40]). Adverse CV events were significantly higher in patients with CVD/CVRF (all CONCLUSIONS: Co-morbid CVD/CVRF is associated with higher COVID-19 severity among patients with cancer, particularly those not receiving active cancer therapy. While infrequent, COVID-19 related CV complications were higher in patients with comorbid CVD/CVRF. (COVID-19 and Cancer Consortium Registry [CCC19]; NCT04354701).

Published
2023

16. Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS) : 14-year update

Author

Dispenzieri, Angela, Coelho, Teresa, Conceição, Isabel, Waddington-Cruz, Márcia, Wixner, Jonas, Kristen, Arnt V., Rapezzi, Claudio, Planté-Bordeneuve, Violaine, Gonzalez-Moreno, Juan, Maurer, Mathew S., Grogan, Martha, Chapman, Doug, Amass, Leslie, Pavia, Pablo Garcia, Tarnev, Ivaylo, Costello, Jose Gonzalez, Briseno, Maria Alejandra Gonzalez Duarte, Schmidt, Hartmut, Drachman, Brian, Barroso, Fabio Adrian, Yamashita, Taro, Lairez, Olivier, Sekijima, Yoshiki, Vita, Giuseppe, Jeon, Eun-Seok, Hanna, Mazen, Slosky, David, Luigetti, Marco, LoRusso, Samantha, Beamud, Francisco Munoz, Adams, David, Moelgaard, Henning, Press, Rayomand, Cirami, Calogero Lino, Nienhuis, Hans, Plana, Josep Maria Campistol, Inamo, Jocelyn, Jacoby, Daniel, Emdin, Michele, Quan, Dianna, Hummel, Scott, Witteles, Ronald, Dori, Amir, Shah, Sanjiv, Lenihan, Daniel, Azevedo, Olga, Murali, Srinivas, Zivkovic, Sasa, Low, Soon Chai, Nativi-Nicolau, Jose, Fine, Nowell, Tallaj, Jose, Tschoepe, Carsten, Torrón, Roberto Fernandéz, Polydefkis, Michael, Merlini, Giampaolo, Badelita, Sorina, Gottlieb, Stephen, Tauras, James, Correia, Edileide Barros, Ventura, Hector, Gess, Burkhard, Darstein, Felix, Oh, Jeeyoung, Marburger, Tessa, Van Cleemput, Johan, Salutto, Valeria Lujan, Parman, Yesim, Chao, Chi-Chao, Sarswat, Nitasha, Mueller, Christopher, Steidley, David, Ralph, Jeffrey, Warner, Alberta, Cotts, William, Hoffman, James, Rugiero, Marcelo, Misawa, Sonoko, Blanco, Jose Luis Munoz, Davila, Lucia Galan, Sadeh, Menachem, Luo, Jin, Kyriakides, Theodoros, Wang, Annabel, Kaufmann, Horacio, Dispenzieri, Angela, Coelho, Teresa, Conceição, Isabel, Waddington-Cruz, Márcia, Wixner, Jonas, Kristen, Arnt V., Rapezzi, Claudio, Planté-Bordeneuve, Violaine, Gonzalez-Moreno, Juan, Maurer, Mathew S., Grogan, Martha, Chapman, Doug, Amass, Leslie, Pavia, Pablo Garcia, Tarnev, Ivaylo, Costello, Jose Gonzalez, Briseno, Maria Alejandra Gonzalez Duarte, Schmidt, Hartmut, Drachman, Brian, Barroso, Fabio Adrian, Yamashita, Taro, Lairez, Olivier, Sekijima, Yoshiki, Vita, Giuseppe, Jeon, Eun-Seok, Hanna, Mazen, Slosky, David, Luigetti, Marco, LoRusso, Samantha, Beamud, Francisco Munoz, Adams, David, Moelgaard, Henning, Press, Rayomand, Cirami, Calogero Lino, Nienhuis, Hans, Plana, Josep Maria Campistol, Inamo, Jocelyn, Jacoby, Daniel, Emdin, Michele, Quan, Dianna, Hummel, Scott, Witteles, Ronald, Dori, Amir, Shah, Sanjiv, Lenihan, Daniel, Azevedo, Olga, Murali, Srinivas, Zivkovic, Sasa, Low, Soon Chai, Nativi-Nicolau, Jose, Fine, Nowell, Tallaj, Jose, Tschoepe, Carsten, Torrón, Roberto Fernandéz, Polydefkis, Michael, Merlini, Giampaolo, Badelita, Sorina, Gottlieb, Stephen, Tauras, James, Correia, Edileide Barros, Ventura, Hector, Gess, Burkhard, Darstein, Felix, Oh, Jeeyoung, Marburger, Tessa, Van Cleemput, Johan, Salutto, Valeria Lujan, Parman, Yesim, Chao, Chi-Chao, Sarswat, Nitasha, Mueller, Christopher, Steidley, David, Ralph, Jeffrey, Warner, Alberta, Cotts, William, Hoffman, James, Rugiero, Marcelo, Misawa, Sonoko, Blanco, Jose Luis Munoz, Davila, Lucia Galan, Sadeh, Menachem, Luo, Jin, Kyriakides, Theodoros, Wang, Annabel, and Kaufmann, Horacio

Abstract

Background: Transthyretin amyloidosis (ATTR amyloidosis) is a rare, life-threatening disease caused by the accumulation of variant or wild-type (ATTRwt amyloidosis) transthyretin amyloid fibrils in the heart, peripheral nerves, and other tissues and organs. Methods: Established in 2007, the Transthyretin Amyloidosis Outcomes Survey (THAOS) is the largest ongoing, global, longitudinal observational study of patients with ATTR amyloidosis, including both inherited and wild-type disease, and asymptomatic carriers of pathogenic TTR mutations. This descriptive analysis examines baseline characteristics of symptomatic patients and asymptomatic gene carriers enrolled in THAOS since its inception in 2007 (data cutoff: August 1, 2021). Results: This analysis included 3779 symptomatic patients and 1830 asymptomatic gene carriers. Symptomatic patients were predominantly male (71.4%) and had a mean (standard deviation [SD]) age of symptom onset of 56.3 (17.8) years. Val30Met was the most common genotype in symptomatic patients in South America (80.9%), Europe (55.4%), and Asia (50.5%), and more patients had early- versus late-onset disease in these regions. The majority of symptomatic patients in North America (58.8%) had ATTRwt amyloidosis. The overall distribution of phenotypes in symptomatic patients was predominantly cardiac (40.7%), predominantly neurologic (40.1%), mixed (16.6%), and no phenotype (2.5%). In asymptomatic gene carriers, mean (SD) age at enrollment was 42.4 (15.7) years, 42.4% were male, and 73.2% carried the Val30Met mutation. Conclusions: This 14-year global overview of THAOS in over 5000 patients represents the largest analysis of ATTR amyloidosis to date and highlights the genotypic and phenotypic heterogeneity of the disease. ClinicalTrials.gov Identifier: NCT00628745.

Published
2022
Full Text
View/download PDF

18. Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS)

Author

Dispenzieri, Angela, Coelho, Teresa, Conceição, Isabel, Waddington-Cruz, Márcia, Wixner, Jonas, Kristen, Arnt V., Rapezzi, Claudio, Planté-Bordeneuve, Violaine, Gonzalez-Moreno, Juan, Maurer, Mathew S., Grogan, Martha, Chapman, Doug, Amass, Leslie, Pavia, Pablo Garcia, Tarnev, Ivaylo, Costello, Jose Gonzalez, Briseno, Maria Alejandra Gonzalez Duarte, Schmidt, Hartmut, Drachman, Brian, Barroso, Fabio Adrian, Yamashita, Taro, Lairez, Olivier, Sekijima, Yoshiki, Vita, Giuseppe, Jeon, Eun-Seok, Hanna, Mazen, Slosky, David, Luigetti, Marco, LoRusso, Samantha, Beamud, Francisco Munoz, Adams, David, Moelgaard, Henning, Press, Rayomand, Cirami, Calogero Lino, Nienhuis, Hans, Plana, Josep Maria Campistol, Inamo, Jocelyn, Jacoby, Daniel, Emdin, Michele, Quan, Dianna, Hummel, Scott, Witteles, Ronald, Dori, Amir, Shah, Sanjiv, Lenihan, Daniel, Azevedo, Olga, Murali, Srinivas, Zivkovic, Sasa, Low, Soon Chai, Nativi-Nicolau, Jose, Fine, Nowell, Tallaj, Jose, Tschoepe, Carsten, Torrón, Roberto Fernandéz, Polydefkis, Michael, Merlini, Giampaolo, Badelita, Sorina, Gottlieb, Stephen, Tauras, James, Correia, Edileide Barros, Ventura, Hector, Gess, Burkhard, Darstein, Felix, Oh, Jeeyoung, Marburger, Tessa, Van Cleemput, Johan, Salutto, Valeria Lujan, Parman, Yesim, Chao, Chi-Chao, Sarswat, Nitasha, Mueller, Christopher, Steidley, David, Ralph, Jeffrey, Warner, Alberta, Cotts, William, Hoffman, James, Rugiero, Marcelo, Misawa, Sonoko, Blanco, Jose Luis Munoz, Davila, Lucia Galan, Sadeh, Menachem, Luo, Jin, Kyriakides, Theodoros, Wang, Annabel, and Kaufmann, Horacio

Subjects
Male, Amyloid Neuropathies, Familial, Registry, Neurologi, Cardiomyopathy, General Medicine, Amyloidosis, Genetic Profile, Amyloid Neuropathies, Transthyretin, Phenotype, Familial, Neurology, Surveys and Questionnaires, Polyneuropathy, Humans, Prealbumin, Pharmacology (medical), Female, Genetics (clinical)
Abstract

Background Transthyretin amyloidosis (ATTR amyloidosis) is a rare, life-threatening disease caused by the accumulation of variant or wild-type (ATTRwt amyloidosis) transthyretin amyloid fibrils in the heart, peripheral nerves, and other tissues and organs. Methods Established in 2007, the Transthyretin Amyloidosis Outcomes Survey (THAOS) is the largest ongoing, global, longitudinal observational study of patients with ATTR amyloidosis, including both inherited and wild-type disease, and asymptomatic carriers of pathogenic TTR mutations. This descriptive analysis examines baseline characteristics of symptomatic patients and asymptomatic gene carriers enrolled in THAOS since its inception in 2007 (data cutoff: August 1, 2021). Results This analysis included 3779 symptomatic patients and 1830 asymptomatic gene carriers. Symptomatic patients were predominantly male (71.4%) and had a mean (standard deviation [SD]) age of symptom onset of 56.3 (17.8) years. Val30Met was the most common genotype in symptomatic patients in South America (80.9%), Europe (55.4%), and Asia (50.5%), and more patients had early- versus late-onset disease in these regions. The majority of symptomatic patients in North America (58.8%) had ATTRwt amyloidosis. The overall distribution of phenotypes in symptomatic patients was predominantly cardiac (40.7%), predominantly neurologic (40.1%), mixed (16.6%), and no phenotype (2.5%). In asymptomatic gene carriers, mean (SD) age at enrollment was 42.4 (15.7) years, 42.4% were male, and 73.2% carried the Val30Met mutation. Conclusions This 14-year global overview of THAOS in over 5000 patients represents the largest analysis of ATTR amyloidosis to date and highlights the genotypic and phenotypic heterogeneity of the disease. ClinicalTrials.gov Identifier: NCT00628745.

Published
2022
Full Text
View/download PDF

20. Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis

Author

Caponetti, Angelo Giuseppe, primary, Rapezzi, Claudio, additional, Gagliardi, Christian, additional, Milandri, Agnese, additional, Dispenzieri, Angela, additional, Kristen, Arnt V., additional, Wixner, Jonas, additional, Maurer, Mathew S., additional, Garcia-Pavia, Pablo, additional, Tournev, Ivailo, additional, Planté-Bordeneuve, Violaine, additional, Chapman, Douglass, additional, Amass, Leslie, additional, van Cleemput, Johan, additional, Waddington-Cruz, Marcia, additional, Schmidt, Hartmut, additional, Dillmann, Klaus-Ulrich, additional, Mølgaard, Henning, additional, Moreno, Juan Gonzalez, additional, Costello, Jose Gonzalez, additional, Beamud, Francisco Munoz, additional, Davila, Lucia Galan, additional, Adams, David, additional, Inamo, Jocelyn, additional, Lairez, Olivier, additional, Vita, Giuseppe, additional, Merlini, Giampaolo, additional, Cirami, Calogero Lino, additional, Luigetti, Marco, additional, Emdin, Michele, additional, Sekijima, Yoshiki, additional, Jeon, Eun-Seok, additional, Oh, Jeeyoung, additional, Gonzalez Duarte Briseno, Maria Alejandra, additional, Nienhuis, Hans, additional, Coelho, Teresa, additional, Conceicao, Isabel, additional, Azevedo, Olga, additional, Badelita, Sorina, additional, Press, Rayomand, additional, Parman, Yesim, additional, Shah, Sanjiv, additional, Quan, Dianna, additional, Marburger, Tessa, additional, Polydefkis, Michael, additional, Witteles, Ronald, additional, Gottlieb, Stephen, additional, Sarswat, Nitasha, additional, Drachman, Brian, additional, Steidley, David, additional, Hummel, Scott, additional, Slosky, David, additional, Jacoby, Daniel, additional, Nativi-Nicolau, Jose, additional, Tauras, James, additional, Zivkovic, Sasa, additional, Tallaj, Jose, additional, and Lenihan, Daniel, additional

Published
2021
Full Text
View/download PDF

21. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey

Author

Nativi-Nicolau, Jose, primary, Siu, Alfonso, additional, Dispenzieri, Angela, additional, Maurer, Mathew S., additional, Rapezzi, Claudio, additional, Kristen, Arnt V., additional, Garcia-Pavia, Pablo, additional, LoRusso, Samantha, additional, Waddington-Cruz, Márcia, additional, Lairez, Olivier, additional, Witteles, Ronald, additional, Chapman, Doug, additional, Amass, Leslie, additional, Grogan, Martha, additional, Barroso, Fabio Adrian, additional, Van Cleemput, Johan, additional, Fine, Nowell, additional, Schmidt, Hartmut, additional, Gess, Burkhard, additional, Moelgaard, Henning, additional, Planté-Bordeneuve, Violaine, additional, Adams, David, additional, Inamo, Jocelyn, additional, Vita, Giuseppe, additional, Cirami, Calogero Lino, additional, Luigetti, Marco, additional, Emdin, Michele, additional, Sekijima, Yoshiki, additional, Yamashita, Taro, additional, Jeon, Eun-Seok, additional, Gonzalez Duarte Briseno, Maria Alejandra, additional, Nienhuis, Hans, additional, Azevedo, Olga, additional, Campistol Plana, Josep Maria, additional, Moreno, Juan Gonzalez, additional, Costello, Jose Gonzalez, additional, Wixner, Jonas, additional, Parman, Yesim, additional, Shah, Sanjiv, additional, Quan, Dianna, additional, Marburger, Tessa, additional, Polydefkis, Michael, additional, Gottlieb, Stephen, additional, Ralph, Jeffrey, additional, Sarswat, Nitasha, additional, Luo, Jin, additional, Murali, Srinivas, additional, Cotts, William, additional, Drachman, Brian, additional, Steidley, David, additional, Hummel, Scott, additional, Slosky, David, additional, Ventura, Hector, additional, Jacoby, Daniel, additional, Hoffman, James, additional, Tauras, James, additional, Zivkovic, Sasa, additional, Tallaj, Jose, additional, Lenihan, Daniel, additional, and Mueller, Christopher, additional

Published
2021
Full Text
View/download PDF

22. Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE), a Prospective, Longitudinal Clonal Hematopoiesis Cohort and Biorepository

Author

Heimlich, Jonathan, Shannon, Morgan, Olson, Sydney, Silver, Alexander J, Debevec, Ariana, Copeland, Zachary, Vlasschaert, Caitlyn, Snider, Christina, Kishtagari, Ashwin, Brown, Donovan J, Spaulding, Travis, Bhatta, Manasa R, Pugh, Kelly, Stockton, Shannon S, Ulloa, Jessica, Xu, Yaomin, Baljevic, Muhamed, Mohan, Sanjay, Moslehi, Javid J., Jahangir, Eiman, Ferrell, Brent, Jr., Slosky, David, Bick, Alexander G., and Savona, Michael R.

Published
2023
Full Text
View/download PDF

23. Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).

Author

Campbell, Courtney M., LoRusso, Samantha, Dispenzieri, Angela, Kristen, Arnt V., Maurer, Mathew S., Rapezzi, Claudio, Lairez, Olivier, Drachman, Brian, Garcia-Pavia, Pablo, Grogan, Martha, Chapman, Doug, Amass, Leslie, The THAOS investigators, Emdin, Michele, Hanna, Mazen, Azevedo, Olga, Cirami, Calogero Lino, Jacoby, Daniel, Costello, Jose Gonzalez, and Slosky, David

Published
2022
Full Text
View/download PDF

24. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance

Author

Abidi, Maheen, primary, Aboulafia, David M., additional, Accordino, Melissa K., additional, Acoba, Jared D., additional, Ahluwalia, Manmeet S., additional, Ahmad, Syed A., additional, Ajmera, Archana, additional, Alimohamed, Saif I., additional, Altman, Jessica, additional, Angevine, Anne H., additional, Bakouny, Ziad, additional, Bar, Michael H., additional, Bardia, Aditya, additional, Barnholtz-Sloan, Jill S., additional, Barrow McCollough, Briana, additional, Bashir, Babar, additional, Batist, Gerald, additional, Bekaii-Saab, Tanios S., additional, Berg, Stephanie, additional, Bernicker, Eric H., additional, Bhutani, Divaya, additional, Bilen, Mehmet A., additional, Bindal, Poorva, additional, Bishnoi, Rohit, additional, Blau, Sibel, additional, Bohachek, Pamela, additional, Boland, Genevieve, additional, Bonnen, Mark, additional, Bouchard, Gabrielle, additional, Bouganim, Nathaniel, additional, Bowles, Daniel W., additional, Busser, Fiona J., additional, Butt, Omar, additional, Cabal, Angelo, additional, Cabalona, Wilhelmina D., additional, Cabebe, Elwyn C., additional, Caimi, Paolo, additional, Campian, Jian L., additional, Carducci, Theresa M., additional, Chen, James L., additional, Cheng, Alex, additional, Chism, David D., additional, Choueiri, Toni K., additional, Clark, Melanie J., additional, Clement, Jessica M., additional, Connors, Jean M., additional, Cook, Erin, additional, Curran, Catherine R., additional, Daher, Ahmad, additional, Dailey, Mark E., additional, Davis, Elizabeth J., additional, Dawsey, Scott J., additional, Deeken, John F., additional, Del Prete, Salvatore A., additional, Demetri, George D., additional, Desai, Aakash, additional, Doroshow, Deborah B., additional, Durbin, Eric B., additional, Egan, Pamela C., additional, Elias, Rawad, additional, Elkrief, Arielle, additional, Elms, Destry J., additional, Elshoury, Amro, additional, Faller, Bryan, additional, Farmakiotis, Dimitrios, additional, Fecher, Leslie A., additional, Feldman, Lawrence E., additional, Ferrario, Cristiano, additional, Fiala, Mark A., additional, Flora, Daniel B., additional, French, Benjamin, additional, Friese, Christopher R., additional, Fu, Julie C., additional, Gadgeel, Shirish M., additional, Gainor, Justin, additional, Galsky, Matthew D., additional, Gantt, Gerald, additional, Garcia, Jorge A., additional, Gartrell, Benjamin A., additional, Gatti-Mays, Margaret E., additional, Gill, David M., additional, Gillaspie, Erin A., additional, Giordano, Antonio, additional, Glace, (Mary) Grace, additional, Glover, Michael J., additional, Goel, Sanjay, additional, Graber, Jerome J., additional, Griffiths, Elizabeth A., additional, Grivas, Petros, additional, Grover, Punita, additional, Gulati, Anthony P., additional, Gulati, Shuchi, additional, Gupta, Shilpa, additional, Gurley, Michael, additional, Hafez, Navid, additional, Halabi, Susan, additional, Halfdanarson, Thorvardur R., additional, Halmos, Balazs, additional, Hausrath, Daniel J., additional, Hawley, Jessica E., additional, Hennessy, Cassandra, additional, Herbst, Roy S., additional, Hershman, Dawn L., additional, Hoppenot, Claire, additional, Hoskins, Kent F., additional, Hoyo-Ulloa, Irma, additional, Hsu, Emily, additional, Hsu, Chih-Yuan, additional, Hwang, Clara, additional, Islam, Jessica Yasmine, additional, Jabbour, Salma K., additional, Jani, Chinmay, additional, Jha, Alokkumar, additional, Jhawar, Sachin R., additional, Johnson, Douglas B., additional, Joshi, Monika, additional, Kasi, Anup, additional, Kelleher, Kaitlin, additional, Kennecke, Hagen F., additional, Khaki, Ali Raza, additional, Khan, Hina, additional, Khan, Mahir, additional, Kharofa, Jordan, additional, Kloecker, Goetz, additional, Knoble, Jeanna L., additional, Kulkarni, Amit A., additional, Kumar, Vaibhav, additional, Lammers, Philip E., additional, Leighton, John C., additional, Lemmon, Christopher A., additional, Lewis, Mark A., additional, Li, Ang, additional, Li, Xuanyi, additional, Liu, Stephen V., additional, Lo, K.M., additional, Loaiza-Bonilla, Arturo, additional, Logan, Barbara B., additional, Loggers, Elizabeth T., additional, de Lima Lopes, Gilberto, additional, Loree, Jonathan M., additional, LoRusso, Patricia, additional, Low, Clarke A., additional, Lustberg, Maryam B., additional, Lyman, Gary H., additional, Lynch, Ryan C., additional, Madhavan, Subha, additional, Mahadevan, Daruka, additional, Mahmood, Sana Z., additional, Mansoor, Abdul-Hai, additional, Marcum, Michelle, additional, Markham, Merry-Jennifer, additional, Mashru, Sandeep H., additional, Masters, Tyler, additional, Mavromatis, Blanche H., additional, McKay, Rana R., additional, McNair, Christopher, additional, McWeeney, Shannon, additional, Menendez, Alvaro G., additional, Menon, Harry, additional, Mesa, Ruben A., additional, Mico, Vasil, additional, Miller, Chaim, additional, Mishra, Sanjay, additional, Monahan, Ryan S., additional, Morgans, Alicia K., additional, Mulcahy, Mary F., additional, Mundt, Daniel, additional, Mushtaq, Sarah, additional, Nagaraj, Gayathri, additional, Nagle, Sarah, additional, Nakasone, Elizabeth S., additional, Nakayama, John M., additional, Nelson, Heather H., additional, Nemecek, Eneida R., additional, Nguyen, Ryan H., additional, Nizam, Amanda, additional, Nohria, Anju, additional, Nuzzo, Pier Vitale, additional, Ohri, Nitin, additional, Olszewski, Adam J., additional, Owenby, Susie, additional, Painter, Corrie A., additional, Palmer, Joshua D., additional, Panagiotou, Orestis A., additional, Park, Cathleen, additional, Pasquinelli, Mary M., additional, Patel, Jaymin M., additional, Patel, Kanishka G., additional, Peddi, Prakash, additional, Pennell, Nathan A., additional, Peters, Solange, additional, Pilar, Christine, additional, Pillainayagam, Clement, additional, Puc, Matthew, additional, Ramirez, Amelie G., additional, Rathmann, Joerg, additional, Ravindranathan, Deepak, additional, Reid, Sonya A., additional, Reuben, Daniel Y., additional, Revankar, Sanjay G., additional, Reynolds, Kerry L., additional, Rho, Young Soo, additional, Rhodes, Terence D., additional, Rice, Robert L., additional, Riess, Jonathan, additional, Rini, Brian I., additional, Rink, Cameron, additional, Rosen, Lane R., additional, Rosenstein, Lori J., additional, Rosovsky, Rachel P., additional, Routy, Bertrand, additional, Rovito, Marc A., additional, Rubinstein, Samuel M., additional, Saif, M. Wasif, additional, Salazar, Mary, additional, Santos Dutra, Miriam, additional, Schapira, Lidia, additional, Schmidt, Andrew L., additional, Schroeder, Brett A., additional, Schwartz, Gary K., additional, Schwartz, Candice, additional, Schweizer, Michael T., additional, Serrano, Oscar K., additional, Shafer, Danielle A., additional, Shah, Pankil K., additional, Shah, Dimpy, additional, Shah, Mansi R., additional, Shah, Sumit A., additional, Shah, Chintan, additional, Shaw, Grace, additional, Shaya, Justin A., additional, Shyr, Yu, additional, Slosky, David A., additional, Smits, Melissa, additional, Solorzano, Carmen C., additional, Stauffer, Karen, additional, Stockerl-Goldstein, Keith E., additional, Stover, Daniel G., additional, Stratton, Jamie, additional, Stratton, Catherine, additional, Streckfuss, Mitrianna, additional, Subbiah, Suki, additional, Tachiki, Lisa, additional, Tadesse, Eyob, additional, Thompson, Michael A., additional, Topaloglu, Umit, additional, Tucker, Matthew D., additional, Van Allen, Eliezer M., additional, Van Loon, Susan, additional, Vega-Luna, Karen, additional, Venepalli, Neeta K., additional, Verma, Amit, additional, Vikas, Praveen, additional, Vinayak, Shaveta, additional, Vinh, Donald C., additional, Wagner, Michael J., additional, Wall, Sarah, additional, Wang, Lucy L., additional, Warner, Jeremy L., additional, Wehbe, Firas H., additional, Weinstein, Paul L., additional, Weiss, Matthias, additional, Weissmann, Lisa B., additional, Wildes, Tanya M., additional, Williams, Nicole, additional, Wise-Draper, Trisha M., additional, Wood, William A., additional, Wu, Julie Tsu-Yu, additional, Wulff-Burchfield, Elizabeth M., additional, Xie, Zhuoer, additional, Xu, Wenxin, additional, Yeh, Albert C., additional, Yu, Irene S., additional, Yu, Peter Paul, additional, Zacks, Rosemary, additional, Zaman, Qamar Ul, additional, Zaren, Howard, additional, Zhang, Tian, additional, Zhou, Alice Y., additional, Zhu, Huili, additional, Zon, Rebecca L., additional, and Zubiri, Leyre, additional

Published
2020
Full Text
View/download PDF

27. Sa1215 - Majority of Patients with Gastrointestinal Amyloidosis have Upper Gut Mucosal Involvement on Biopsy and Improve with Small Bowel Bacterial Overgrowth Treatment

Author

Naik, Rishi D., primary, Wong, Rochelle, additional, Reed, Thomas, additional, Cornell, Robert, additional, Concepcion, Beatrice, additional, John, Roy, additional, Hoffman, Robert, additional, Miller, Robert, additional, Peltier, Amanda, additional, Slosky, David, additional, Langone, Anthony, additional, Goodman, Stacey, additional, and Horst, Sara N., additional

Published
2018
Full Text
View/download PDF

30. Fulminant Myocarditis with Combination Immune Checkpoint Blockade

Author

Johnson, Douglas B., primary, Balko, Justin M., additional, Compton, Margaret L., additional, Chalkias, Spyridon, additional, Gorham, Joshua, additional, Xu, Yaomin, additional, Hicks, Mellissa, additional, Puzanov, Igor, additional, Alexander, Matthew R., additional, Bloomer, Tyler L., additional, Becker, Jason R., additional, Slosky, David A., additional, Phillips, Elizabeth J., additional, Pilkinton, Mark A., additional, Craig-Owens, Laura, additional, Kola, Nina, additional, Plautz, Gregory, additional, Reshef, Daniel S., additional, Deutsch, Jonathan S., additional, Deering, Raquel P., additional, Olenchock, Benjamin A., additional, Lichtman, Andrew H., additional, Roden, Dan M., additional, Seidman, Christine E., additional, Koralnik, Igor J., additional, Seidman, Jonathan G., additional, Hoffman, Robert D., additional, Taube, Janis M., additional, Diaz, Luis A., additional, Anders, Robert A., additional, Sosman, Jeffrey A., additional, and Moslehi, Javid J., additional

Published
2016
Full Text
View/download PDF

32. Autologous Hematopoietic Cell Transplant (AHCT) Offers Prolonged Progression Free and Overall Survival in Patients with Light Chain Amyloidosis (AL) Compared with Chemotherapy Alone

Author

Ukaegbu, Oluchi, primary, Sethi, Tarsheen, additional, Goodman, Stacey, additional, Rubinstein, Samuel Matthew, additional, Hung, Rebecca, additional, Jagasia, Madan H., additional, Kassim, Adetola A., additional, Lacy, Shelton, additional, Langone, Anthony, additional, Lenihan, Daniel, additional, Savani, Bipin N., additional, Slosky, David, additional, and Cornell, Robert F., additional

Published
2016
Full Text
View/download PDF

33. Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma

Author

Chen, John H., primary, Lenihan, Daniel J., additional, Phillips, Sharon E., additional, Jagasia, Madan H., additional, Goodman, Stacey A., additional, Kassim, Adetola A., additional, Lacy, Shelton L., additional, McDonagh, Kevin T., additional, Moslehi, Javid J., additional, Sethi, Tarsheen K., additional, Slosky, David A., additional, Ukaegbu, Oluchi C., additional, and Cornell, Robert F., additional

Published
2015
Full Text
View/download PDF

35. Prospective Study of Cardiac Events during Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma

Author

Cornell, Robert Frank, Ky, Bonnie, Weiss, Brendan M, Du, Liping, Carver, Joseph R, Cohen, Adam D., Engelhardt, Brian G, Garfall, Alfred L., Goodman, Stacey A, Harrell, Shelton Lacy, Kassim, Adetola A., Jadhav, Trafina, Jagasia, Madan, Moslehi, Javid, O'Quinn, Rupal, Savona, Michael R., Slosky, David, Smith, Amanda, Stadtmauer, Edward A., Vogl, Dan T., Innis-Shelton, Racquel, Waxman, Adam, and Lenihan, Daniel

Published
2017
Full Text
View/download PDF

41. Left Atrial Hypertension After Repeated Catheter Ablations for Atrial Fibrillation

Author

Shoemaker, M. Benjamin, primary, Hemnes, Anna R., additional, Robbins, Ivan M., additional, Langberg, Jonathan J., additional, Ellis, Christopher R., additional, Aznaurov, Sam G., additional, Fredi, Joseph L., additional, Slosky, David A., additional, Roden, Dan M., additional, Murray, Katherine T., additional, Piana, Robert N., additional, Mendes, Lisa A., additional, and Whalen, S. Patrick, additional

Published
2011
Full Text
View/download PDF

46. Diagnosis of Urinary Tract Infection.

Author

Slosky, David A. and Todd, James K.

Subjects
URINARY tract infections, DIAGNOSIS, STAPHYLOCOCCUS, COMMUNICABLE diseases, CLINICAL medicine, MEDICAL microbiology
Abstract

The results of 787 consecutive suprapubic specimens in children were studied. Ninety-two patients with 128 positive cultures were reviewed. Sixty-five children had documented urinary tract infection (UTI) proven by other cultures. Of these, 55 per cent had colony counts less than the traditional 100,000 colony forming units/ml., and 9 per cent had colony counts less than 10.000. Organisms usually regarded as "contaminants" (Staphylococcus epidermidis, mixed organisms) were occasionally proven to cause UTI. [ABSTRACT FROM AUTHOR]

Published
1977
Full Text
View/download PDF

47. A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis.

Author

Haque, Tamanna, Shastri, Aditi, Desai, Pinkal, Xie, Zhuoer, Hammond, Danielle, King, Zoe, Kishtagari, Ashwin, Madanat, Yazan F., Abaza, Yasmin, Silver, Alexander J., Singh, Abhay, Borate, Uma M., Heimlich, J. Brett, Slosky, David A., Bolton, Kelly L., Patnaik, Mrinal S., Bick, Alexander G., Verma, Amit K., Jaiswal, Siddhartha, and Steensma, David P.

Subjects
*SOMATIC mutation, *MEDICAL screening, *CLINICAL trials, *HEMATOPOIESIS, *RESEARCH personnel
Abstract

Summary The age‐associated mutational state of clonal haematopoiesis (CH) is linked to multiple adverse health outcomes. As higher risk CH can lead to progressive neoplastic or vascular disease, there is interest in developing clinical trials to mitigate risk associated with CH. Given the high prevalence of CH, data from clinical trials could have broad public health implications for screening and therapy. Thoughtful consideration is needed to design trials that are both clinically relevant and avoid overmedicalization. Here, we summarize clinical studies of CH to date and provide suggestions and guidance on how to approach designing CH‐focused therapeutic clinical trials. These recommendations are derived from discussions among clinical researchers and scientists emanating from the Inaugural Meeting on Somatic Mutations and Predisease in October 2021. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. Outcomes in patients with cardiac amyloidosis and implantable cardioverter-defibrillator.

Author

Kim EJ, Holmes BB, Huang S, Lugo R, Al Aboud A, Goodman S, Hung RR, Slosky D, Stevenson WG, Michaud GF, and John RM

Subjects
Aged, Aged, 80 and over, Case-Control Studies, Death, Sudden, Cardiac, Female, Humans, Middle Aged, Risk Factors, Stroke Volume, Treatment Outcome, Ventricular Function, Left, Amyloidosis diagnosis, Amyloidosis therapy, Defibrillators, Implantable
Abstract

Aims: Cardiac amyloidosis (CA) is associated with increased mortality due to arrhythmias, heart failure, and electromechanical dissociation. However, the role of an implantable cardioverter-defibrillator (ICD) remains unclear. We conducted case-control study to assess survival in CA patients with and without a primary prevention ICD and compared outcomes to an age, sex, and device implant year-matched non-CA group with primary prevention ICD., Methods and Results: There were 91 subjects with CA [mean age= 71.2 ± 10.2, female 22.0%, 49 AL with Mayo Stage 2.9 ± 1.0, 41 transthyretin amyloidosis (ATTR), 1 other] followed by Vanderbilt Amyloidosis centre. Patients with ICD (n = 23) were compared with those without (n = 68) and a non-amyloid group with ICD (n = 46). All subjects with ICD had implantation for primary prevention. Mean left ventricular ejection fraction was 36.2% ± 14.4% in CA with ICD, 41.0% ± 10.6% in CA without ICD, and 33.5% ± 14.4% in non-CA patients. Over 3.5 ± 3.1 years, 6 (26.1%) CA, and 12 (26.1%) non-CA subjects received ICD therapies (P = 0.71). Patients with CA had a significantly higher mortality (43.9% vs. 17.4%, P = 0.002) compared with the non-CA group. Mean time from device implantation to death was 21.8 months in AL and 22.8 months in ATTR patients. There was no significant difference in mortality between CA patients who did and did not receive an ICD (39.0% vs. 46.0%, P = 0.59)., Conclusions: Despite comparable event rates patients with CA had a significantly higher mortality and ICDs were not associated with longer survival. With the emergence of effective therapy for AL amyloidosis, further study of ICD is needed in this group., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.)

Published
2020
Full Text
View/download PDF

49. Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room.

Author

Zhao DX, Leacche M, Balaguer JM, Boudoulas KD, Damp JA, Greelish JP, Byrne JG, Ahmad RM, Ball SK, Cleator JH, Deegan RJ, Eagle SS, Fong PP, Fredi JL, Hoff SJ, Jennings HS 3rd, McPherson JA, Piana RN, Pretorius M, Robbins MA, Slosky DA, and Thompson A

Subjects
Adult, Aged, Aged, 80 and over, Angioplasty, Balloon, Coronary adverse effects, Cardiac Catheterization methods, Cohort Studies, Combined Modality Therapy, Coronary Artery Bypass adverse effects, Coronary Disease therapy, Female, Follow-Up Studies, Humans, Intraoperative Care methods, Male, Middle Aged, Probability, Radiography, Interventional, Retrospective Studies, Risk Assessment, Sensitivity and Specificity, Statistics, Nonparametric, Stents, Treatment Outcome, Vascular Patency, Angioplasty, Balloon, Coronary methods, Coronary Angiography methods, Coronary Artery Bypass methods, Coronary Disease diagnostic imaging, Coronary Disease surgery, Operating Rooms
Abstract

Objectives: This study sought to report our experience with a routine completion angiogram after coronary artery bypass surgery (CABG) and simultaneous (1-stop) percutaneous coronary intervention (PCI) at the time of CABG performed in the hybrid catheterization laboratory/operating room., Background: The value of a routine completion angiogram after CABG and 1-stop hybrid CABG/PCI remains unresolved., Methods: Between April 2005 and July 2007, 366 consecutive patients underwent CABG surgery, with (n = 112) or without (n = 254) concomitant 1-stop PCI (hybrid), all with completion angiography before chest closure. Among the 112 1-stop hybrid CABG/PCI patients, 67 (60%) underwent a planned hybrid procedure based on pre-operative assessment, whereas 45 (40%) underwent open-chest PCI (unplanned hybrid) based on intraoperative findings., Results: Among the 796 CABG grafts (345 left internal mammary artery, 12 right internal mammary artery/radial, and 439 veins), 97 (12%) angiographic defects were identified. Defects were repaired with either a minor adjustment of the graft (n = 22, 2.8%), with intraoperative open-chest PCI (unplanned hybrid, n = 48, 6%) or with traditional surgical revision (n = 27, 3.4%). Hybrid patients had clinical outcomes similar to standard CABG patients., Conclusions: Routine completion angiography detected 12% of grafts with important angiographic defects. One-stop hybrid coronary revascularization is reasonable, safe, and feasible. Combining the tools of the catheterization laboratory and operating room greatly enhances the options available to the surgeon and cardiologist for patients with complex coronary artery disease.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results